-+ 0.00%
-+ 0.00%
-+ 0.00%

VISTAGEN THERAPEUTICS, - DISCONTINUATION RATE DUE TO ADVERSE EVENTS WAS 1.6%, NONE ATTRIBUTED TO FASEDIENOL

Reuters·09/22/2026 12:32:10